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Abstract L-Asparaginase is known to catalyze the hydrolysis
of L-asparagine to L-aspartic and ammonia, but little is known
about its action on peptides. When we incubated L-asparagi-
nases puri¢ed either from Escherichia coli or Erwinia chrysan-
themi ^ commonly used as chemotherapeutic agents because of
their antitumour activity ^ with eight small L-aspartylpeptides
such as L-aspartylserineamide, L-aspartylalanineamide, L-aspar-
tylglycineamide and L-aspartylglycine, we found that both L-as-
paraginases could catalyze the hydrolysis of ¢ve of them yield-
ing L-aspartic acid and amino acids or peptides. Our data show
that L-asparaginases can hydrolyze L-aspartylpeptides and sug-
gest that L-asparaginase therapy may a¡ect the metabolism of
L-aspartylpeptides present in human body. " 2002 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
L-Asparaginase (L-asparagine aminohydrolase; EC 3.5.1.1)
is widely used in the treatment of acute lymphoblastic leuke-
mia (ALL) because of its ability to catalyze the deamidation
of L-asparagine to L-aspartic acid. Its antitumour activity is
based on the fact that certain tumour cells, especially ALL
tumour cells, have a nutritional dependence on an external
supply of Asn. In contrast, normal cells are protected from
Asn-starvation during the L-asparaginase therapy due to their
ability to produce this amino acid. In clinical use, the L-aspar-
aginases, which are mainly puri¢ed from Escherichia coli or
Erwinia chrysanthemi, are toxic drugs and their therapeutic
response rarely occurs without some evidence of toxicity.
The common toxic side e¡ects of asparaginase therapy include
hypersensitivity reactions, leukopenia, hyperglycemia, neuro-
logical seizures and pancreatitis [1^3]. The toxicity is partially
attributable to the glutaminase activity of these enzymes [4,5].
Investigations of the substrate speci¢city of bacterial L-aspar-
aginases have shown that, in addition to L-asparagine and
L-glutamine, these enzymes are able to catalyze the hydrolysis
of D-asparagine, succinamic acid [4], L-aspartate-L-hydrox-
amate, L-aspartate-L-methylester, DL-NK-ethylasparagine [6]
and certain N4-substituted L-asparagine derivatives [7], and
de-aminate small peptides with carboxyl-terminal asparagine
residues [4].
L-Aspartylpeptides are present in normal mammalian body
£uids [8,9] and tissues [10] and their formation in rat kidney
has been demonstrated [10]. Some of these peptides have been
suggested to represent end products of protein degradation
[11]. We have recently shown that the lysosomal enzyme gly-
cosylasparaginase (GA) is active toward L-aspartylpeptides
[12]. In this study we have investigated whether two thera-
peutically used L-asparaginases, puri¢ed from E. coli and E.
chrysanthemi, can catalyze the hydrolysis of L-aspartylpepti-
des. Our results show that both L-asparaginases catalyze the
hydrolysis of certain L-aspartylpeptides, and particularly small
size L-aspartyl amino acid amides such as H-Asp(Ser-NH2)-
OH (L-aspartylserineamide). The results suggest that at the
doses used in ALL, L-asparaginase therapy may a¡ect the
metabolism of L-aspartylpeptides.
2. Materials and methods
EC-2-type L-asparaginase puri¢ed from E. coli, Elspar0 (EcAII),
was purchased from Merck, PA, USA. L-Asparaginase derived from
E. chrysanthemi, Erwinase0 (ErAII), was a product of Ipsen, Berk-
shire, UK. L-Asparagine monohydrate was purchased from Fluka,
Buchs, Switzerland. GlcNAc-Asn (L-aspartylglucosamine), ASAT (as-
partate aminotransferase) and MDH (malic dehydrogenase) were
products of Sigma Chemical, MO, USA. NADH (nicotinamide
adenine dinucleotide) was purchased from Boehringer, Mannheim,
Germany. H-Asp(Phe-OMe)-OH (L-aspartame) and H-Asp(Gly)-OH
(L-aspartylglycine) were products of Bachem Feinchemikalien, Buben-
dorf, Switzerland. H-Asp(Ser-NH2)-OH and other amides were pre-
pared as previously described [13,14]. Other peptides were prepared as
reported [13].
The kinetic parameters for the hydrolysis of L-aspartylpeptides were
carried out in vessels thermostated at 23‡C with a spectrophotometric
assay [15]. Brie£y, various concentrations of Asn, L-aspartylpeptides
or GlcNAc-Asn were incubated for 15 min in microplate wells in the
presence of stock solution containing NADH, MDH and ASAT.
Then, either EcAII or ErAII was added to give a ¢nal volume of
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250 Wl and the ¢nal L-asparaginase activity of 91 U/l. Into blank wells,
an aliquot of 50 mM Tris^HCl, pH 7.5, was added instead of enzyme
to determine if there was any free Asp in the peptide solution. The
blank values were subtracted from the actual measurements, because
free Asp, as an impurity, could give false positive results. The rate of
the absorbance decrease at 340 nm was followed with a Tecan Spec-
traFLUOR spectrophotometer, Tecan Austria, Gro«dig, Austria, and
the change in the substrate concentration was calculated as described
previously [16]. The kinetic parameters were calculated using the Enz-
pack for Windows, version 1.4, Biosoft software package.
3. Results
When L-asparaginases from E. coli (EcAII) and E. chrysan-
themi (ErAII) were incubated in the presence of eight di¡erent
L-aspartylpeptides at 23‡C, both enzymes catalyzed the hydro-
lysis of ¢ve of these peptides to L-aspartic acid and the resid-
ual peptide or amino acid. The kinetic parameters of the hy-
drolysis of Asn, L-aspartylpeptides and GlcNAc-Asn are
summarized in Table 1.
The relative hydrolysis rates of di¡erent L-aspartylpeptides
varied markedly depending on the peptide. H-Asp(Ser-NH2)-
OH was hydrolyzed by the two L-asparaginases at half of the
rate of Asn. The L-asparaginases also catalyzed the hydrolysis
of other L-aspartylpeptide amides, but their relative rates were
considerably lower: the hydrolysis rates of L-aspartylalanine-
amide and L-aspartylglycineamide were 1/10^1/50 of that of
Asn. The hydrolysis rate of H-Asp(Gly)-OH was approxi-
mately 1/1000 of that of Asn. The two enzymes showed di¡er-
ences in their substrate speci¢city towards the L-aspartylpep-
tides that were hydrolyzed at low relative rates. ErAII
catalyzed the hydrolysis of H-Asp((Gly)4-OH))-OH, but this
compound was not hydrolyzed by EcAII. EcAII could hydro-
lyze H-Asp(Phe-OMe)-OH, but this peptide remained unhy-
drolyzed by ErAII. The relative hydrolysis rate of L-aspartyl-
glycineamide was approximately 10-fold higher than that of
the corresponding unsubstituted peptide, H-Asp(Gly)-OH.
Neither of the L-asparaginases was able to hydrolyze
GlcNAc-Asn. Fig. 1 shows schematically the hydrolytic reac-
tions catalyzed by L-asparaginases.
4. Discussion
The combined evidence indicates that in spite of the com-
pact size of the catalytic cavity present in L-asparaginases
[17,18] they are capable of accommodating small L-aspartyl-
peptides or amides leading to acylation of the L-asparagine
L-carboxamido group. On the contrary, the lysosomal GA
possesses a more spacious binding site, which is able to accept
bulkier glucosyl residues, accounting for its activity towards
larger size L-aspartylpeptides [12].
Earlier studies on the substrate speci¢city of bacterial L-as-
paraginases have characterized some special features for their
potential substrates. A free K-carboxyl group of the L-aspar-
agine moiety is essential for the hydrolysis of the substrate
and a free K-amino group of L-asparagine participates in the
binding of the amino acid to L-asparaginase [4]. Small pep-
tides with a carboxyl-terminal L-asparagine residues are de-
aminated and L-aspartoalkylamides with straight chain alkyl
substituents are hydrolyzed by E. carotovora L-asparaginase
[4]. Derivatives of L-asparagine with substituents on N4-posi-
tion not greater than a methoxy group are hydrolyzed at a
considerable rate by E. coli asparaginase [7]. In our study,
H-Asp(Ser-NH2)-OH, which is quite bulky when compared
to N4-methoxy-L-asparagine, is hydrolyzed half as fast as L-
asparagine by both Erwinia and E. coli asparaginase. Further-
more, our ¢nding that the L-asparaginase-catalyzed hydrolysis
of L-aspartylpeptide amides is faster than that of the corre-
sponding L-aspartylpeptides suggests that, because of its
known hydrophobic character, the L-asparaginase substrate
binding site does not tolerate a charged functional group on
the C-terminal amino acid. This also applies to the GA-cata-
lyzed hydrolysis of L-aspartylpeptides [12].
L-Asparaginases and GA have many biochemical properties
Table 1
Kinetic parameters of L-asparaginase from E. coli (EcAII) and E. chrysanthemi (ErAII) for the hydrolysis of L-Asn, L-aspartylpeptides and
GlcNAc-Asn at 23‡C
Compound Kcat/Km (M31 s31) Vmax (WM/min) Km (WM) Relative rate (%)
EcAII ErAII EcAII ErAII EcAII ErAII EcAII ErAII
H-Asn-OHa 973 000 3 180 000 22.7 16 130 90 100 100
H-Asp(Ser-NH2)-OH 148 000 629 000 11.8 8.5 460 240 52 53
H-Asp(Ala-NH2)-OH 76 400 833 000 1.9 1.4 140 30 8.2 8.6
H-Asp(Gly-NH2)-OH 7150 12 500 0.51 0.35 410 500 2.2 2.1
H-Asp(Gly-OH)-OHb;c 47 144 0.07 0.02 8 510 2 230 0.3 0.1
H-Asp(Phe-OMe)-OH 1530 0 0.04 0 150 0 0.2 0
H-Asp((Gly)4-OH))-OH 0 6 380 0 0.05 0 140 0 0.3
H-Asp(Gly-Gln-OH)-OHb 0 0 0 0 0 0 0 0
H-Asp(Gly-Val-OH)-OHb 0 0 0 0 0 0 0 0
H-Asp(GlcNAcNH)-OHd 0 0 0 0 0 0 0 0
Compounds marked with a^d are present in human body.
aCooney et al. [28].
bBuchanan et al. [8].
cPisano et al. [11].
dRowley et al. [29].
Fig. 1. Schematic illustration of the reactions catalyzed by L-aspara-
ginase.
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in common, including the polymeric subunit structure [19] and
the ability to hydrolyze L-asparagine [20] to L-aspartic acid
and ammonia. It has been suggested that the hydrolysis of
L-aspartyl compounds catalyzed by GA is initiated by the
binding of the aspartyl moiety to the active site of the enzyme
through its free K-amino and K-carboxyl groups [19,21]. GA
uses the Q-hydroxyl and K-amino group of its L-chain N-ter-
minal threonine as an active site nucleophile and general base,
respectively [22], in the formation of L-aspartylated enzyme,
which is subsequently deacylated by water to L-aspartic acid.
E. coli L-asparaginase [23], Pseudomonas 7A glutaminase-as-
paraginase [24] and E. chrysanthemi [25] use the Q-hydroxyl
group of a threonine residue located in a £exible loop of the
enzyme protein as an active site nucleophile.
In conclusion, our results suggest that high-dose L-aspara-
ginase therapy, for example, used in the treatment of ALL
may hydrolyze L-aspartylpeptides present in human body.
The toxicity of L-asparaginases has partially been attributed
to the glutaminase activity of these enzymes [4,5]. L-Aspara-
ginases puri¢ed from E. coli (EC-2) or Erwinia have relative
activities toward L-glutamine of 2^3% [26,27] or 9% [4] of that
toward L-asparagine, respectively. We found that the relative
rates of hydrolysis of H-Asp(Ser-NH2)-OH by E. coli and
Erwinia asparaginases were 52% and 53% of that of L-aspar-
agine and thus signi¢cantly higher than those reported in
literature for L-glutamine. The corresponding hydrolysis rates
of L-aspartylalanineamide and L-aspartylglycineamide were 8^
9% and ca 2% of that of Asn, respectively, and thus on the
same range as the hydrolysis of L-glutamine by these enzymes.
Whether the hydrolysis of L-aspartylpeptides is of signi¢cance
in mediating the numerous side e¡ects of L-asparaginase ther-
apy in ALL patients remains to be elucidated.
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